AIM-HI Accelerator Fund

AIM-HI Accelerator Fund announces winners of the 2025 Venture Competition

The AIM-HI Accelerator Fund has selected two companies, ResNovas Therapeutics and Chiara Biosciences, as winners of the 2025 Venture Competition. Both companies have demonstrated innovative approaches to targeted protein degradation and drug discovery, with potential to transform cancer treatment.

SourceAIM-HI Accelerator Fund·DateOct 9, 2025

AIM-HI Accelerator Fund portfolio firm receives Virginia Catalyst funding

A portfolio start-up company of the AIM-HI Accelerator Fund, ILCT is developing engineered therapeutic interleukins for cancer treatment. The grant will support collaboration with Virginia Commonwealth University towards development of its commercialization efforts.

SourceAIM-HI Accelerator Fund·DateDec 30, 2019